30951-66-7

Usage

Uses

Used in Organic Synthesis:
2-(3-Bromophenyl)propan-2-ol is used as a reagent in organic synthesis for the preparation of other organic compounds. Its unique structure allows it to participate in various chemical reactions, making it a valuable component in the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-(3-Bromophenyl)propan-2-ol is used as a precursor for the synthesis of biologically active molecules. Its potential applications include the development of new drugs and therapeutic agents, contributing to advancements in medicine and healthcare.
Used in Research and Development Laboratories:
2-(3-Bromophenyl)propan-2-ol is utilized in research and development laboratories as a tool for investigating various chemical reactions and processes. Its unique properties make it an essential component in studying and understanding the mechanisms of chemical transformations, furthering scientific knowledge and innovation in the field of chemistry.
Used in Building Blocks for Biologically Active Molecules:
2-(3-Bromophenyl)propan-2-ol serves as a building block for the creation of biologically active molecules. Its structural features enable the development of new compounds with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science.

Upstream product

• 24398-88-7 ethyl 3-bromobenzoate 
• 75-16-1 methylmagnesium bromide 
• 2142-63-4 1-(3-Bromophenyl)ethanone 
• 5433-01-2 1-bromo-3-isopropylbenzene 
• 618-89-3 methyl 3-bromobenzoate 
• 74-88-4 methyl iodide 
• 585-76-2 m-bromobenzoic acid 
• 676-58-4 methylmagnesium chloride 
• 917-64-6 methyl magnesium iodide 
• 1711-09-7 3-bromobenzoyl chloride 

Downstream Products

• 7073-94-1 1-bromo-2-isopropylbenzene 
• 5433-01-2 1-bromo-3-isopropylbenzene 
• 25108-58-1 1-bromo-3-isopropenylbenzene 
• 77826-66-5 1-(3-bromophenyl)-1-methylethylium 
• 917024-66-9 [1-(3-Bromophenyl)-1-(methyl)ethyl]oxytrimethylsilane 
• 1198567-62-2 2-{3-[2-(1H-indol-6-yl)imidazo[1,2-a]pyridin-6-yl]phenyl}propan-2-ol 
• 1198567-64-4 2-[3-(2-thien-3-ylimidazo[1,2-a]pyridin-6-yl)phenyl]propan-2-ol 
• 1198567-69-9 2-[3-(2-benzo[d] isoxazol-3-ylimidazo[1,2-a]pyridin-6-yl)phenyl]propan-2-ol 
• 1198567-70-2 5-[3-[1-Methyl-1-(trimethylsilanyloxy)ethyl]phenyl]pyridin-2-ylamine 
• 1198568-49-8 2-{3-[2-(1H-indol-5-yl)imidazo[1,2-a]pyridin-6-yl]phenyl}propan-2-ol 
• 1198211-08-3 2-[3-(6-Aminopyridin-3-yl)phenyl]propan-2-ol 
• 1198567-63-3 2-[3-(2-Chloroimidazo[1,2-a]pyridin-6-yl)-phenyl]propan-2-ol 
• 1333113-32-8 C₂₄H₃₂O₇ 
• 1333113-36-2 C₂₃H₃₀O₆ 

Relevant academic research and scientific papers

Stepwise benzylic oxygenation via uranyl-photocatalysis

Stepwise oxygenation at the benzylic position (1°, 2°, 3°) of aromatic molecules was comprehensively established under ambient conditions via uranyl photocatalysis to produce carboxylic acids, ketones, and alcohols, respectively. The accuracy of the stepwise oxygenation was ensured by the tunability of catalytic activity in uranyl photocatalysis, which was adjusted by solvents and additives demonstrated through Stern–Volmer analysis. Hydrogen atom transfer between the benzylic position and the uranyl catalyst facilitated oxygenation, further confirmed by kinetic studies. Considerably improved efficiency of flow operation demonstrated the potential for industrial synthetic application.

Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes

According to the binding mode of ABBV-744 with bromodomains and the cape space of HDAC, the novel selective HDAC/BRD4 dual inhibitors were designed and synthesized by the pharmacophore fusion strategy. Evaluating the biomolecular activities through SARs exploration identified three kinds of selective dual inhibitors 41c (HDAC1/BRD4), 43a (pan-HDAC/BRD4) and 43d (HDAC6/BRD4(BD2)), whose target-related cellular activities in MV-4-11 cells were also confirmed. Significantly, the selective dual inhibitor 41c (HDAC1/BRD4) exhibited synergistic effects against MV-4-11 cells, which strongly induced G0/G1 cell cycle arrest and apoptosis, and the first HDAC6/BRD4(BD2) dual inhibitor was found. This study provides support for selective HDAC/BRD4 dual inhibitors as epigenetic probes based on pyrrolopyridone core for the future biological evaluation in different cancer cell lines.

Pyrrolopyridone compound as well as preparation method, composition and application thereof

The invention relates to a pyrrolopyridone compound or pharmaceutically acceptable salts thereof, and a preparation method and application thereof. The pyrrolopyridone compound has a structure as shown in a formula I which is described in the specification. The compound has the characteristic of BRD4 and HDAC double-target inhibition activity and/or has the characteristic of a function of targetedubiquitination degradation of BRD4 protein, and can be applied to related diseases such as tumor resistance related to the target.

Synthesis of 4H-1,3-Benzoxazines via Metal- and Oxidizing Reagent-Free Aromatic C-H Oxygenation

An unprecedented electrochemical aromatic C-H oxygenation reaction for the synthesis of 4H-1,3-benzoxazines from easily available N-benzylamides is reported. These oxidative cyclization reactions proceed in a transition metal- and oxidizing reagent-free fashion and produce H2 as only theoretical byproduct. Adapting the C-H oxygenation reaction in an electrochemical microreactor has been demonstrated.

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy.

Glucosylceramide synthase inhibitors

The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.

1,3,5-TRIAZINE-2-AMINE DERIVATIVES, PREPARATION THEREOF AND DIAGNOSTIC AND THERAPEUTIC USE THEREOF

The present invention relates to compounds corresponding to formula (I) in which: - R1 represents a substituted phenyl; - R2 represents: - a substituted phenyl; - a heteroaromatic group, the said group being unsubstituted or substituted one or more times; - R3 represents a group Alk; - R4 represents a hydrogen atom or a (C1-C4)alkyl; - R5 represents a hydrogen atom, a (C3-C6)cycloalkyl or a (C1-C4)alkyl-O-Alk; - or alternatively R4 and R5, together with the nitrogen atom to which they are attached, constitute a heterocyclic radical chosen from: azetidin-1-yl, pyrrolidin-1-yl, piperid-1-yl, morpholin-4-yl; - R6 represents a group -COOAlk, a group -CONH2 or a group -NHSO2 Alk; - Alk represents a (C1-C4)alkyl, which is unsubstituted or substituted one or more times with a halogen atom; in the form of the base or of an acid-addition salt. Preparation process and diagnostic and therapeutic use

Access to "friedel-Crafts-Restricted" tert -alkyl aromatics by activation/methylation of tertiary benzylic alcohols

Herein we describe a two-step protocol to prepare m-tert-alkylbenzenes. The appropriate tertiary benzylic alcohols are activated with SOCl2 or concentrated HCl and then treated with trimethylaluminum, affording the desired products in 68-97% yields (22 examples). This reaction sequence is successful in the presence of a variety of functional groups, including acid-sensitive and Lewis-basic groups. In addition to t-Bu groups, 1,1-dimethylpropyl and 1-ethyl-1-methylpropyl groups can also be installed using this method.

POLYSUBSTITUTED 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF

Compounds of formula (I): wherein R, R1, R2, R3, R4, and X are as defined in the disclosure, or an acid addition salt thereof, and the therapeutic use and process of synthesis thereof.

POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF

Compounds of formula (I): wherein R, R1, R2, R3, R4 and X are as defined in the disclosure, or an acid addition salt thereof, and the therapeutic use and process of synthesis thereof.